Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe.

• Tác giả: O Akkerman, A B Andersen, H Atshemyan, Á Bakos, A Bjarnason, T T Brehm, J Bruchfeld, D Chesov, L R Codecasa, E V Davidavičienė, R Duarte, A M Dyrhol-Riise, M Fréchet Jachym, G Günther, O Kirakosyan, M Knappik, O Konstantynovska, L Kuksa, C Lange, M J Makek, K Manika, A M McLaughlin, I Muylle, C Nita, Ş Özkara, V Parris, D Pieridou, M Reimann, M Santin, M Skowroński, I Solovic, M Stosic, P Svetina, T Togonidze, T Vasankari, P Viiklepp, N Yatskevich, S Zeynel
• Ngôn ngữ: eng
• Ký hiệu phân loại: 305.568 +Alienated and excluded classes
• Thông tin xuất bản: France : IJTLD open , 2025
• Bộ sưu tập: NCBI
• ID: 173262

Tóm tắt

BACKGROUND: Anecdotal information suggests that clinical practice regarding the use of putative hepatoprotective agents in TB treatment varies across countries in the WHO European Region. METHODS: Between November 2023 and May 2024, we conducted a standardised questionnaire survey on the use of putative hepatoprotective agents in patients receiving TB treatment among Tuberculosis Network European Trials Group (TBnet) representatives in countries in the WHO European Region. RESULTS: We received valid responses from 37 of 53 countries (69.8%), with 16 (43.2%) reporting regular use of putative hepatoprotective agents during anti-TB treatment. Half of these countries ( CONCLUSIONS: Putative hepatoprotective agents are widely used as an adjunct to TB treatment in the WHO European Region, particularly in the countries of the former Soviet Union, some of which have included them in their national guidelines.